Pfizer Target of Unusually High Options Trading (PFE)
Pfizer Inc. (NYSE:PFE) was the target of some unusual options trading activity on Tuesday. Investors acquired 28,773 call options on the stock. This is an increase of approximately 217% compared to the typical volume of 9,078 call options.
In other Pfizer news, insider Rady A. Johnson sold 4,500 shares of the stock in a transaction on Friday, March 10th. The shares were sold at an average price of $34.19, for a total transaction of $153,855.00. Following the completion of the sale, the insider now owns 54,963 shares of the company’s stock, valued at approximately $1,879,184.97. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Charles H. Hill sold 36,000 shares of the stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $34.07, for a total transaction of $1,226,520.00. Following the sale, the insider now directly owns 57,329 shares of the company’s stock, valued at approximately $1,953,199.03. The disclosure for this sale can be found here. Insiders have sold a total of 71,470 shares of company stock valued at $2,449,150 in the last three months. 0.07% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in the company. Asset Planning Services Ltd. increased its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. Fusion Family Wealth LLC purchased a new position in shares of Pfizer during the fourth quarter worth approximately $109,000. Israel Discount Bank of New York purchased a new position in shares of Pfizer during the first quarter worth approximately $109,000. AlphaMark Advisors LLC increased its position in shares of Pfizer by 37.3% in the first quarter. AlphaMark Advisors LLC now owns 3,226 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 876 shares in the last quarter. Finally, Orrstown Financial Services Inc. increased its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Institutional investors and hedge funds own 69.53% of the company’s stock.
Pfizer (NYSE:PFE) opened at 32.22 on Friday. Pfizer has a 52 week low of $29.83 and a 52 week high of $37.39. The company has a market capitalization of $192.28 billion, a price-to-earnings ratio of 27.12 and a beta of 0.94. The company has a 50 day moving average of $33.63 and a 200 day moving average of $32.89.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.02. The business had revenue of $12.78 billion during the quarter, compared to the consensus estimate of $13.09 billion. Pfizer had a net margin of 13.50% and a return on equity of 23.18%. The firm’s revenue was down 1.7% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 earnings per share. On average, equities analysts forecast that Pfizer will post $2.55 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 1st. Shareholders of record on Friday, May 12th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Wednesday, May 10th. This represents a $1.28 dividend on an annualized basis and a yield of 3.97%. Pfizer’s dividend payout ratio is presently 110.35%.
Several brokerages have weighed in on PFE. Citigroup Inc cut shares of Pfizer from a “neutral” rating to a “sell” rating and dropped their price target for the company from $38.00 to $31.00 in a research report on Tuesday. Barclays PLC reissued a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. Sanford C. Bernstein reissued a “buy” rating and set a $37.00 price target on shares of Pfizer in a research report on Wednesday, May 3rd. BMO Capital Markets reissued a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Finally, Jefferies Group LLC reissued a “neutral” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $37.54.
TRADEMARK VIOLATION WARNING: “Pfizer Target of Unusually High Options Trading (PFE)” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/05/19/pfizer-target-of-unusually-high-options-trading-pfe-2.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.